<DOC>
	<DOC>NCT00574236</DOC>
	<brief_summary>Primary objective is to determine the effectiveness of the combination of bortezomib and doxorubicin in patients with metastatic breast cancer. The trial format is a single arm Phase II design wherein patients are treated with bortezomib IV on days 1, 4, 8, and 11 and with doxorubicin IV on days 1 and 8 of a 21-day cycle.</brief_summary>
	<brief_title>Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Cytologically or histologically confirmed metastatic breast cancer Measurable or evaluable disease Age &gt; 18, PS 0,1,2 MUGA &gt; 45% Received one or fewer chemotherapies or investigational regimens for metastatic disease, no limit to the number of prior hormonal therapies. May have had single agent Herceptin and/or Herceptin plus singleagent chemotx. Must meet designated laboratory criteria within 14 days of enrollment Doxorubicin for metatstatic disease. Pregnant or lactating. Active infections, no myocardial infarction within 2 months of enrollment. Investigational drugs within 14 days of enrollment. Chemotherapy, radiotherapy, hormonal therapy or other investigational therapy within 4 weeks of enrollment. Neuropathy that is &gt; grade 2. Active brain mets. Hypersensitivity to bortezomib, boron, or mannitol.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>